Legal & General Group Plc Takes $71.42 Million Position in Revolution Medicines, Inc. $RVMD

Legal & General Group Plc acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 381,366 shares of the company’s stock, valued at approximately $71,422,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. The Manufacturers Life Insurance Company acquired a new position in Revolution Medicines in the 2nd quarter worth about $11,048,000. L2 Asset Management LLC bought a new position in Revolution Medicines in the second quarter valued at about $215,000. Nan Fung Group Holdings Ltd bought a new position in Revolution Medicines in the second quarter valued at about $3,605,702,000. Cibc World Market Inc. acquired a new stake in shares of Revolution Medicines during the second quarter valued at about $2,639,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Revolution Medicines during the second quarter valued at about $432,000. Institutional investors own 94.34% of the company’s stock.

Insider Buying and Selling

In related news, CFO Jack Anders sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the sale, the chief financial officer directly owned 123,269 shares in the company, valued at $20,749,870.77. This represents a 13.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Margaret A. Horn sold 60,400 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the sale, the chief operating officer directly owned 158,222 shares of the company’s stock, valued at $25,342,417.74. This represents a 27.63% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 212,497 shares of company stock valued at $38,206,486 over the last 90 days. 7.60% of the stock is currently owned by corporate insiders.

Revolution Medicines Stock Up 2.7%

Shares of RVMD opened at $221.15 on Friday. The company has a market capitalization of $47.40 billion, a PE ratio of -25.07 and a beta of 1.39. Revolution Medicines, Inc. has a 12 month low of $37.56 and a 12 month high of $224.31. The stock’s 50-day moving average price is $192.43 and its two-hundred day moving average price is $148.17. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the company posted ($1.31) earnings per share. On average, analysts anticipate that Revolution Medicines, Inc. will post -8.82 EPS for the current year.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Analysts Set New Price Targets

Several research analysts have recently issued reports on RVMD shares. Mizuho upped their price objective on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a research note on Monday, July 6th. TD Cowen upgraded shares of Revolution Medicines to a “strong-buy” rating in a report on Monday. Piper Sandler lifted their target price on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Guggenheim boosted their target price on shares of Revolution Medicines from $235.00 to $240.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $193.28.

Revolution Medicines Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.